Briol, Tertulo M.
HRN: 22-75-14 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/15/2023
CEFTRIAXONE 1G (VIAL)
03/15/2023
03/22/2023
IV
2gms
OD
Erysieplas; H Pylori
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft TissueIntra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes